RESEARCH ARTICLE
Cell Engineering and Molecular Pharming for Biopharmaceuticals
M.A Abdullah*, 1, Anisa ur Rahmah1, A.J Sinskey2, C.K Rha3
3 Biomaterials Science and Engineering Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
Article Information
Identifiers and Pagination:
Year: 2008Volume: 2
First Page: 49
Last Page: 61
Publisher ID: TOMCJ-2-49
DOI: 10.2174/1874104500802010049
Article History:
Received Date: 18/3/2008Revision Received Date: 20/4/2008
Acceptance Date: 21/4/2008
Electronic publication date: 14/5/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Biopharmaceuticals are often produced by recombinant E. coli or mammalian cell lines. This is usually achieved by the introduction of a gene or cDNA coding for the protein of interest into a well-characterized strain of producer cells. Naturally, each recombinant production system has its own unique advantages and disadvantages. This paper examines the current practices, developments, and future trends in the production of biopharmaceuticals. Platform technologies for rapid screening and analyses of biosystems are reviewed. Strategies to improve productivity via metabolic and integrated engineering are also highlighted.
